Avsnittsbeskrivning
The FDA’s regulatory framework for Artificial Intelligence (AI) in the drug product life cycle has transitioned from early exploration to a structured, risk-based credibility assessment framework. According to the latest draft guidance, this framework applies to the use of AI to produce information or data intended to support regulatory decision-making regarding the safety, effectiveness, or quality of human and animal drugs, biological products, and combination products.
The Risk-Based Credibility Assessment Framework
The core of the FDA's current regulatory thinking is a 7-step process…
Webbplats: bioedgepartners.substack.com

